Alnylam Pharmaceuticals Q2 2024 Adj. EPS $0.56 Beats $(1.08) Estimate, Sales $659.825M May Not Be Comparable To $444.107M Estimate
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals reported Q2 2024 adjusted EPS of $0.56, significantly beating the estimated loss of $(1.08). Sales were $659.825 million, which may not be comparable to the estimated $444.107 million.
August 01, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals reported a strong Q2 2024 with adjusted EPS of $0.56, beating the estimated loss of $(1.08). Sales were $659.825 million, which may not be comparable to the estimated $444.107 million.
The significant beat in both EPS and sales figures is likely to positively impact Alnylam Pharmaceuticals' stock price in the short term. The market generally reacts favorably to such earnings surprises.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100